Screening and determination of synthetic PDE-5 inhibitors in adulterated sexual enhancement supplements

• Main Authors: Jairoun, Ammar Abdulrahman, Al-Hemyari, Sabaa Saleh, Shahwan, Moyad, Zyoud, Sa'ed H., Ibrahim, Baharudin, Zyoud, Samer H.
• Format: Article
• Published: MDPI 2022
• Subjects: QD Chemistry; RA Public aspects of medicine; RS Pharmacy and materia medica
• Online Access: http://eprints.um.edu.my/41060/

This paper reports an important investigation and quantification of adulteration of sexual enhancement supplements with prescription medicines available in United Arab Emirates (UAE): tadalafil, sildenafil and vardenafil. A total of 158 sexual enhancement supplements were collected and analyzed in the current study. The samples were screened using REVERSE-phase liquid chromatography tandem high-resolution mass spectrometry/mass spectrometry (RP-HPLC-MS/MS). Of all sexual enhancements, 12.7% (95% CI: 7.4-18) contained undeclared sildenafil, 3.8% (95% CI: 0.78-6.81) contained undeclared tadalafil and 1.9% (95% CI: 0.25-4.05) contained undeclared vardenafil. Of all sexual enhancement supplements, 13.9% (95% CI: 8.5-19.4) contained significant concentrations of sildenafil, tadalafil or vardenafil. While the study found relatively low levels of undeclared pharmaceutical ingredients in the sexual enhancement dietary supplements available on the UAE market, it is likely that patients with ED tend to consume multiple such supplements daily, thereby exposing themselves to highly elevated cumulative levels.